Under the proposed transaction, LifePoint shareholders will receive $65 per share in cash for each share of LifePoint they own. Mr. Foti and his law firm are seeking to determine whether $65 per share is adequate or if that amount undervalues LifePoint. They are also examining whether the process used to determine the share buyout price was adequate.
The proposed deal was announced July 23, and the $65 shareholders will get for each share owned is an about 36 percent premium to LifePoint’s closing price of $47.90 July 20, according to The Wall Street Journal.
The proposed deal needs approval from regulators and LifePoint shareholders.
More articles on legal and regulatory issues:
12 latest lawsuits involving hospitals
Ex-drug company executive gets 15 years in prison for $50M pill distribution plot
Congress considers 340B changes
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.